Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Woodford Investment Management leads round into OxSyBio, the second Oxford University spinout from Oxford Nanopore founder Hagan Bayley

OxSyBio, an Oxford University biotech spinout company developing 3D printer technology capable of printing biological materials with a diverse range of therapeutic purposes, has secured £10m in Series A financing from Woodford Investment Management alongside new and existing backers.

OxSyBio has a unique 3D printing platform which enables it to assemble the building blocks of life. The synthetic biology company’s ultimate ambition is to fabricate therapeutic tissues for patients using living cells or non-living ‘artificial’ cells, or hybrid materials. These tissues have the potential to revolutionise the growing field of regenerative medicine, allowing for the literal printing of new tissues that can be used to repair or replace parts of the body damaged through disease or injury.

Find out more (OUI website)

Similar stories

Oxford spin-out Optellum attains CE marking for its early lung cancer diagnosis AI technology

The contribution of individual features on clinical imaging scans to the performance of the LCP-CNN cancer risk prediction model developed in Oxford was investigated.

Oxford University retains top spot for spinout generation in the UK

Oxford University has been ranked first in the UK for turning academic research into spinout companies, according to a new report published today by data analyst firm Beauhurst.

The glass half full man: Professor Chas Bountra and Oxford's innovative future

Forget the TV clichés about Oxford – all punting and pass the port. The 925-year-old university is full of the most amazing people who are helping and benefiting the world, well beyond the quads and spires, says Professor Chas Bountra, the university’s Pro-Vice-Chancellor for Innovation. After the events of the last two years - and the COVID-19 vaccine [2.5 billion doses delivered and counting] - this most enthusiastic champion of Oxford maintains there can be no doubt, innovation is part and parcel of the historic university’s future. Who knows what is coming next, he says, expectantly.

Exscientia and University of Oxford launch “Xcellomics” program to expedite early-stage academic research and translate novel biology into future drug discovery

Exscientia and the University of Oxford's Target Discovery Institute (TDI) today announced the formation of Xcellomics – a program designed to source cellular functional assays from the global academic community to develop novel screens and identify targets and therapeutic candidates for unmet medical needs.

Professor Collins awarded Sir Jules Thorn Translational Biomedical Research Award 2021

Professor Sally Collins has been awarded the prestigious and highly competitive Sir Jules Thorn Translational Biomedical Research Award 2021 for further translational development of the OxNNet Toolkit.

Sir Jon Symonds joins Pharmacology as a Visiting Fellow

The Department of Pharmacology is delighted to announce the appointment of Sir Jonathan Symonds CBE, Chair of the Board of GlaxoSmithKline, as a Visiting Fellow. Jon has been Chairman of the Board at GSK since September 2019.